Intuniv is only the second non-stimulant treatment for the condition, following Lilly's off-patent drug Strattera. Perry Sternberg, senior vice president, Neuroscience Business Unit, Shire said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback